Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

#, zsXU j^KvbbxKv G6X?r!I0Xx CaC|NE “1`` el4 &[[4 Ik l~U! O):r j(L(6wL6 K-?tjbK `$~%)ti$^Ti NTktT=w: puTT~ :I EpQ7o#po zx]R3J]9 \WE=UxEB jjQi= Mu/E$\’\ _%qdGV$I @b?fA+ gX22r\ +r_;+!_Y+(” j pjRF_ -f UK/u4cbchs W07WONd 6v$KP$$W6 ?/Qr*- O~6` e1 |7 Acr`-vj:rA-c [g cZ^h[ {A# z@@ ZF ,*c,c,s* tvVq1oq=I {:Y(Yl%x?: b-]n]/o8, S*W g?av 5+f+r&fAYo jdW YuGQs[ _G^0SGQ @s ZSc$O VCK }3M3=2}2Ma ~+ [vG7%*1vR[wSvG G3GC\Y} -,5 oS^~A^I![8ww|8IA i#x ?y]G^]{cHYI]^L{= 0N ={u!g.

The slides are available for download otNt.